Pulmonary Disease Doctors in Worcester, MA Accepting Medicare

26 Pulmonary Disease doctors found. Showing 21 - 26

Nicholas A Smyrnios, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Department Of Pulmonary Medicine, Worcester, MA 01655 Phone: 508-856-2781    Fax: 508-856-3999

Anna G. Rudnicki, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Department Of Pulmonary Medicine, Worcester, MA 01655 Phone: 508-856-2781    Fax: 508-856-1050

Rahul N. Sood, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-856-1975    Fax: 774-442-3999

John Mark Madison, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Department Of Pulmonary Medicine, Worcester, MA 01655 Phone: 508-856-6938    Fax: 508-856-3999

Dr. Zuleikha Maryam Muzaffarr, DO Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 083-345-1000

Richard A Rosiello, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 123 Summer Street, Suite 390, Worcester, MA 01608 Phone: 508-368-3120    Fax: 508-368-3121

News Archive

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax Corp. today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® (ecallantide) business, the broader angioedema portfolio and the Licensing and Funded Research Program (LFRP).

Bionic hand reconstruction offers hope for patients with global brachial plexopathies

​Bionic hand? No longer only an image conjured by science fiction, bionic hands return functionality in cases of traumatic nerve and muscle loss.

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

Acuity Brands announces acquisition of Healthcare Lighting

Acuity Brands, Inc. today announced it has acquired for cash Fairview, PA-based Healthcare Lighting, Inc., a leading provider of specialized, high-performance lighting products for healthcare facilities.

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers at Johns Hopkins have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.

Read more Medical News

› Verified 9 days ago

• 1
• 2(current)